David Geffen School of Medicine at UCLA-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2014

  1. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

    Movement Disorders, Vol. 29, Núm. 4, pp. 470-478